drugset
drugset / Trial / NCT02172131

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

NCT02172131 ↗

Phase 1 Terminated 64 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate safety, tolerability, and pharmacokinetics (PK) of single i.v. doses of BI 1744 CL

Timeline

Start
2006-10
Primary completion
2007-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 0.5 ug Intravenous
Subject Olodaterol Small molecule 2.5 ug Intravenous
Subject Olodaterol Small molecule 5 ug Intravenous
Subject Olodaterol Small molecule 10 ug Intravenous
Subject Olodaterol Small molecule 15 ug Intravenous
Subject Olodaterol Small molecule 20 ug Intravenous
Subject Olodaterol Small molecule 25 ug Intravenous
Subject Olodaterol Small molecule 30 ug Intravenous

Indications

No indication recorded.